| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2025 ( Subtotal = $201,801,200 ) (Continued on the next page) |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R21AG093815 | Digital detection of handwriting impairments in patients with atypical Alzheimer’s disease and frontotemporal dementia | 000 | 1 | NIH | 6/16/2025 | $441,100 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01CA272496 | Targeting PLK1 in RAS mutant chronic myelomonocytic leukemia | 000 | 3 | NIH | 3/14/2025 | $384,419 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01HL166238 | Electrochemical Catheter for Prevention of Central Line-Associated Bloodstream Infection | 000 | 3 | NIH | 2/19/2025 | $382,186 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01AG093767 | Premenopausal bilateral oophorectomy and biomarkers of Alzheimer’s and cerebrovascular diseases | 000 | 1 | NIH | 5/14/2025 | $1,979,481 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | U01AI179609 | Mitochondrial Malfunction in T Cell Aging and Tissue Inflammation | 000 | 2 | NIH | 2/12/2025 | $563,609 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01DK132718 | Noninvasive assessment of portal hypertension and hepatic interstitial pressure with advanced magnetic resonance elastography | 000 | 3 | NIH | 2/27/2025 | $310,878 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | OT2OD039849 | All of Us Biobank | 000 | 1 | NIH | 7/22/2025 | $80,770 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | OT2OD039849 | All of Us Biobank | 000 | 1 | NIH | 7/22/2025 | $13,400,000 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R21HD116957 | Defining the role of haplotypes and rejection pathways in placental villitis | 000 | 1 | NIH | 7/25/2025 | $443,850 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | OT2OD039849 | All of Us Biobank | 000 | 1 | NIH | 7/22/2025 | $5,751,974 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R21CA302968 | CCNE1 is synthetically lethal with drug induced nuclear Cathepsin L (nCTSL) | 000 | 1 | NIH | 7/23/2025 | $412,429 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | K23DK141902 | Choosing the Right BPH Procedure: Evaluating Patient Priorities and the Impact of Cost on BPH Surgical Preference | 000 | 1 | NIH | 7/24/2025 | $203,676 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R21AI188373 | Ebola Virus Life Cycle Modeling In Vivo | 000 | 1 | NIH | 7/29/2025 | $441,100 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R21AI187691 | Antagonistic actions of IRF4 and BACH2 in regulating Germinal Center B cell fates and promoting Lymphomagenesis | 000 | 1 | NIH | 7/23/2025 | $441,098 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01CA265050 | New Therapuetics for Pancreatic Cancer | 001 | 4 | NIH | 6/9/2025 | $598,329 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01DK122948 | Lipotoxicity and Liver Inflammation | 001 | 6 | NIH | 2/28/2025 | $525,565 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01AI170535 | Characterizing the role of CSDE1 as a critical co-factor for VSV replication. | 000 | 3 | NIH | 2/12/2025 | $391,395 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01AG044615 | Respiratory Control in Old Age | 002 | 13 | NIH | 7/31/2025 | $602,958 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01HL180379 | Epigenetic regulation of donor heart preservation mediated by Brd4 | 000 | 1 | NIH | 8/11/2025 | $739,562 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01DK098468 | Role of Circadian Misalignment in Beta-cell Failure in Type 2 Diabetes | 001 | 14 | NIH | 6/30/2025 | $516,603 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01CA283663 | Next-Generation Whole-Body MRI for Detection and Assessment of Therapy Response in Bone Lesions | 002 | 3 | NIH | 6/18/2025 | $582,617 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01AR083873 | Local Delivery of AdipoRon to Treat Arthrofibrosis | 000 | 1 | NIH | 7/7/2025 | $342,975 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | F30CA294722 | DNA aptamers as tools for toxin delivery to glioblastoma | 001 | 1 | NIH | 7/10/2025 | $0 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01CA275074 | Evaluation of novel tomosynthesis density measures in breast cancer risk prediction | 000 | 3 | NIH | 3/19/2025 | $604,359 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | F30CA294722 | DNA aptamers as tools for toxin delivery to glioblastoma | 000 | 1 | NIH | 7/10/2025 | $49,738 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R03CA292132 | Targeting Ferroptosis in Cholangiocarcinoma with siRNA-based Nanovesicles | 000 | 1 | NIH | 7/23/2025 | $161,400 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01EB031790 | Super Resolution for Improved Multislice Prostate MRI | 001 | 4 | NIH | 6/25/2025 | $62,245 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01EB036987 | AI-assisted quantitative photon-counting-detector CT imaging for cytogenetic risk prediction and treatment response in multiple myeloma | 000 | 1 | NIH | 3/19/2025 | $546,874 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01EB031790 | Super Resolution for Improved Multislice Prostate MRI | 000 | 4 | NIH | 3/17/2025 | $560,204 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01HL167796 | Targeting Senescence Specific Mechanisms of NF-κB Activation to Reverse Chronic Pulmonary Fibrosis | 001 | 2 | NIH | 7/16/2025 | $58,902 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01HL167796 | Targeting Senescence Specific Mechanisms of NF-κB Activation to Reverse Chronic Pulmonary Fibrosis | 000 | 2 | NIH | 3/5/2025 | $530,118 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01AG076469 | A novel cilium-to-nucleus axis promotes cellular senescence | 001 | 4 | NIH | 6/17/2025 | $26,076 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01AG076469 | A novel cilium-to-nucleus axis promotes cellular senescence | 000 | 4 | NIH | 3/6/2025 | $293,355 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01CA275074 | Evaluation of novel tomosynthesis density measures in breast cancer risk prediction | 001 | 3 | NIH | 5/22/2025 | $67,152 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01HL142068 | T Cell Immunity in Giant Cell Arteritis | 001 | 6 | NIH | 5/3/2025 | $581,040 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01CA258239 | Novel multipronged Immunovirotherapy Approach for GBM Treatment | 001 | 5 | NIH | 5/22/2025 | $33,437 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01CA258239 | Novel multipronged Immunovirotherapy Approach for GBM Treatment | 000 | 5 | NIH | 3/4/2025 | $300,935 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01HL145268 | Measuring arterial material properties using wave-based approaches with ultrasound and computational models | 002 | 7 | NIH | 8/5/2025 | $68,507 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01HL145268 | Measuring arterial material properties using wave-based approaches with ultrasound and computational models | 000 | 7 | NIH | 2/26/2025 | $616,578 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | F31NS141217 | Identifying molecular mechanisms contributing to disease etiology and the neurological symptoms associated with pediatric DPD deficiency | 000 | 1 | NIH | 1/28/2025 | $48,974 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R21EB037399 | G-Quadruplex-Based Supramolecular Assemblies as Activatable Contrast Agents for In Vitro and In Vivo Fluorescence Imaging of Estrogen Receptor | 000 | 1 | NIH | 8/13/2025 | $443,850 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | U10CA180882 | Alliance Statistics and Data Management Center | 000 | 11 | NIH | 3/14/2025 | $4,779,823 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01HL164416 | Targeting Immune-Responsive Gene 1 (Irg1) and Itaconate for Cardioprotection of the Donor Heart for Transplantation | 002 | 4 | NIH | 7/29/2025 | $647,639 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | U10CA180882 | Alliance Statistics and Data Management Center | 001 | 11 | NIH | 7/10/2025 | $3,190,073 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01DK137231 | Engineering microcapsules for scalable differentiation of human pluripotent stem cells into hepatocytes | 001 | 2 | NIH | 6/18/2025 | $55,572 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R21CA283539 | RNA methylation as a novel effector of SETD2 in kidney cancer | 001 | 2 | NIH | 5/22/2025 | $18,863 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01DK137231 | Engineering microcapsules for scalable differentiation of human pluripotent stem cells into hepatocytes | 000 | 2 | NIH | 2/20/2025 | $500,141 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R21CA283539 | RNA methylation as a novel effector of SETD2 in kidney cancer | 000 | 2 | NIH | 3/20/2025 | $169,773 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01AG050603 | Molecular and structural imaging in atypical Alzheimer's disease: a longitudinal study | 001 | 10 | NIH | 6/10/2025 | $63,472 |
|
